ERBB2 and breast carcinoma: The first Phase III clinical trial investigating the efficacy of an anti-HER2 vaccine (E37) given as adjuvant therapy to women with early-stage node-positive breast cancer (the Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment, or PRESENT, trial) is currently ongoing.